Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
13 Nov 2025
// PR NEWSWIRE BIO
https://www.prnewswire.com/news-releases/domain-therapeutics-appoints-boston-based-pharma-leader-jean-marie-cuillerot-md-as-chief-medical-officer-302614484.html
28 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-28/domain-therapeutics-doses-first-patients-in-phase-iii-trial-of-dt-7012-targeting-ccr8-in-solid-tumors-1
30 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/domain-therapeutics-presents-novel-data-addressing-key-challenges-in-oncology-at-aacr-2025-302441512.html
01 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/domain-therapeutics-to-present-data-on-its-gpcr-lead-programs-at-aacr-annual-meeting-2025-302415784.html
20 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/domain-therapeutics-discloses-dt-9046-as-a-groundbreaking-oral-drug-candidate-for-inflammatory-diseases-302406153.html
06 Jun 2024
// BUSINESSWIRE
Drugs in Development
Details:
DT-7012 is a large molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.
Lead Product(s): DT-7012
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: Assistance Publique – Hôpitaux de Paris
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2025
Details : DT-7012 is a large molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2025
Details:
DT-7012 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): DT-7012
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Domain Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 11, 2025
Lead Product(s) : DT-7012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Domain Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DT-7012 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2025
Details:
DT-9045 is a novel protease-activated receptor 2 (PAR2) negative allosteric modulator, small molecule drug candidate. It is being evaluated for the treatment of cancer.
Lead Product(s): DT-9045
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024
Lead Product(s) : DT-9045
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Domain Therapeutics to Present DT-9045 Data, a Novel Modulator for Immuno-oncology
Details : DT-9045 is a novel protease-activated receptor 2 (PAR2) negative allosteric modulator, small molecule drug candidate. It is being evaluated for the treatment of cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2024
Details:
Through the agreement, the company will focus on the clinical development of DT-7012, a CCR8 antibody candidate. Currently, it is being evaluated in preclinical trial studies for Neoplasms.
Lead Product(s): DT-7012
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Recipient: Chime Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 12, 2024
Lead Product(s) : DT-7012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Chime Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Domain Therapeutics and Chime Announce Manufacturing Deal for Anti-Ccr8 Cancer Antibody
Details : Through the agreement, the company will focus on the clinical development of DT-7012, a CCR8 antibody candidate. Currently, it is being evaluated in preclinical trial studies for Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 12, 2024
Details:
A grant supports clinical progress of DT-7012, an anti-CCR8 monoclonal antibody, in preclinical studies for cutaneous T-cell lymphoma and other neoplasms.
Lead Product(s): DT-7012
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Agence Nationale de la Recherche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 25, 2024
Lead Product(s) : DT-7012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Agence Nationale de la Recherche
Deal Size : Undisclosed
Deal Type : Funding
Domain Therapeutics Awarded Grant To Progress CCR8 Antibody Candidate
Details : A grant supports clinical progress of DT-7012, an anti-CCR8 monoclonal antibody, in preclinical studies for cutaneous T-cell lymphoma and other neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 25, 2024
Details:
DT-9081 is an oral small molecule product which, by blocking the EP4 receptor present on immune cells, is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system.
Lead Product(s): DT-9081
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2023
Details : DT-9081 is an oral small molecule product which, by blocking the EP4 receptor present on immune cells, is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2023
Details:
DT-9081 is an oral small molecule drug candidate, which is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system, by blocking the EP4 receptor present on immune cells.
Lead Product(s): DT-9081
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2022
Details : DT-9081 is an oral small molecule drug candidate, which is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system, by blocking the EP4 receptor present on immune cells.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2022
Details:
DT-9081 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): DT-9081
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2022
DT-9081 Study in Participants with Advanced, Recurrent or Metastatic Solid Tumours
Details : DT-9081 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2022
Details:
DT-9081 is a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models.
Lead Product(s): DT-9081,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 06, 2022
Lead Product(s) : DT-9081,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DT-9081 is a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2022
Details:
A2a/A2b antagonist candidate, M1069, a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectable solid tumors.
Lead Product(s): 5-Methyltetrazole
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: $261.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 28, 2022
Lead Product(s) : 5-Methyltetrazole
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $261.0 million
Deal Type : Collaboration
Details : A2a/A2b antagonist candidate, M1069, a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectable solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
